129 related articles for article (PubMed ID: 31809978)
1. Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells.
Miyake N; Ochi N; Yamane H; Fukazawa T; Ikeda T; Yokota E; Takeyama M; Nakagawa N; Nakanishi H; Kohara H; Nagasaki Y; Kawahara T; Ichiyama N; Yamatsuji T; Naomoto Y; Takigawa N
Lung Cancer; 2020 Jan; 139():170-178. PubMed ID: 31809978
[TBL] [Abstract][Full Text] [Related]
2. Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells.
Nakagawa N; Miyake N; Ochi N; Yamane H; Takeyama M; Nagasaki Y; Ikeda T; Yokota E; Fukazawa T; Nakanishi H; Harada D; Kiura K; Takigawa N
Exp Cell Res; 2021 Dec; 409(2):112940. PubMed ID: 34808132
[TBL] [Abstract][Full Text] [Related]
3. Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
Maehara S; Usuda J; Ishizumi T; Ichinose S; Ohtani K; Inoue T; Imai K; Furumoto H; Kudo Y; Kajiwara N; Ohira T; Ikeda N
Int J Oncol; 2015 Feb; 46(2):741-9. PubMed ID: 25385189
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
[TBL] [Abstract][Full Text] [Related]
5. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
[TBL] [Abstract][Full Text] [Related]
6. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
[TBL] [Abstract][Full Text] [Related]
7. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
8. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
[TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma.
Ida L; Yamaguchi T; Yanagisawa K; Kajino T; Shimada Y; Suzuki M; Takahashi T
Cancer Sci; 2016 Feb; 107(2):155-61. PubMed ID: 26661061
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.
Hwang KE; Kim YS; Jung JW; Kwon SJ; Park DS; Cha BK; Oh SH; Yoon KH; Jeong ET; Kim HR
Oncotarget; 2015 Oct; 6(30):29482-96. PubMed ID: 26334320
[TBL] [Abstract][Full Text] [Related]
11. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R
Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
Leon LG; Gemelli M; Sciarrillo R; Avan A; Funel N; Giovannetti E
Curr Drug Targets; 2014; 15(14):1331-40. PubMed ID: 25483224
[TBL] [Abstract][Full Text] [Related]
14. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
[TBL] [Abstract][Full Text] [Related]
15. Critical role of the Ror-family of receptor tyrosine kinases in invasion and proliferation of malignant pleural mesothelioma cells.
Saji T; Nishita M; Ogawa H; Doi T; Sakai Y; Maniwa Y; Minami Y
Genes Cells; 2018 Jul; 23(7):606-613. PubMed ID: 29845703
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma.
Satoh T; Tatsuta T; Sugawara S; Hara A; Hosono M
Oncotarget; 2017 Jun; 8(26):42466-42477. PubMed ID: 28476017
[TBL] [Abstract][Full Text] [Related]
17. Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma.
Liu Y; Yang H; Chen T; Luo Y; Xu Z; Li Y; Yang J
PLoS One; 2015; 10(5):e0127092. PubMed ID: 25978653
[TBL] [Abstract][Full Text] [Related]
18. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.
Hojjat-Farsangi M; Ghaemimanesh F; Daneshmanesh AH; Bayat AA; Mahmoudian J; Jeddi-Tehrani M; Rabbani H; Mellstedt H
PLoS One; 2013; 8(4):e61167. PubMed ID: 23593420
[TBL] [Abstract][Full Text] [Related]
20.
Dell'Anno I; Barbarino M; Barone E; Giordano A; Luzzi L; Bottaro M; Migliore L; Agostini S; Melani A; Melaiu O; Catalano C; Cipollini M; Silvestri R; Corrado A; Gemignani F; Landi S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32659970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
